Getinge 2022 Annual Report
Getinge 2022 Annual Report
Introduction
Strategy
Corporate Governance
Annual Report
Sustainability Report
Other information
Contents
Note 3 cont.
SEK M
EMEA
of which, Sweden
Americas
APAC
Total
Intangible assets, tangible assets
Net sales
and right-of-use assets
2022
2021
2022
10,130
10,167
12,052
549
492
2,335
11,467
10,249
18,959
2021
10,805
2,113
16,603
6,695
6,632
867
28,292
27,049
31,878
860
28,268
Net sales per business area and region, 2022
SEK M
Acute Care Therapies
Life Science
Surgical Workflows
Total
EMEA
4,151
1,721
4,259
10,130
Americas
7,624
1,447
2,395
11,467
APAC
3,510
858
2,327
6,695
Total
15,285
4,026
8,981
28,292
Net sales per business area and region, 2021
SEK M
EMEA
Americas
APAC
Total
Acute Care Therapies
Life Science
Surgical Workflows
Total
4,661
1,547
3,959
10,167
7,105
1,319
1,825
10,249
3,760
692
2,180
6,632
15,527
3,558
7,965
27,049
Net sales per business area and revenue type, 2022
SEK M
Capital goods
Recurring revenue
Total
Acute Care Therapies
Life Science
Surgical Workflows
Total
4,099
1,940
5,062
11,101
11,186
2,086
3,919
17,191
15,285
4,026
8,981
28,292
Net sales per business area and revenue type, 2021
SEK M
Acute Care Therapies
Life Science¹)
Surgical Workflows
Total¹)
Capital goods
5,090
Recurring revenue
10,437
Total
15,527
1,727
1,830
3,558
4,475
11,292
3,489
15,757
7,965
27,049
1) Restatement of the distribution of net sales between capital goods and recurring revenue amounting to SEK 969 M have been made for comparative figures for year 2021.
All net sales of DPTE-BetaBag in Life Science are recognized as recurring revenue instead of capital goods as from January 1, 2022. See Note 2.
85
Getinge's operations are secondarily reported by geographic area.
The US accounted for 36% (33) of the Group's sales and was the
only country that accounted for more than 10% of total sales.
Refer also to page 181 for a list of the Group's 20 largest markets.
The geographic areas' consolidation is conducted in accordance
with the same policies as for the Group in its entirety.View entire presentation